文献速递肾移植慢性肾脏病

肾移植后糖皮质激素、甲状旁腺激素与体成分对骨密度和骨结构的影响

Corticosteroid, Parathyroid Hormone, and Body Composition Associations With Bone Density and Structure Following Kidney Transplantation.
PubMed 文献 · Am J Kidney Dis · 2025-11-06

本研究为24个月前瞻性队列研究,纳入60例新发肾移植受者和361名健康对照。肾移植后前6个月肌肉和脂肪增加,但骨小梁密度和腰椎骨密度下降;6个月后皮质骨密度随甲状旁腺激素下降而增加,但皮质厚度持续变薄,糖皮质激素剂量与骨密度变化负相关。

要点

  • 肾移植后6个月内骨小梁密度和腰椎骨密度下降,6个月后部分部位骨密度改善。
  • 糖皮质激素剂量与脊柱、髋部及皮质骨、骨小梁密度变化负相关。
  • 较高的BMI和四肢骨骼肌质量指数与髋部及脊柱骨密度增加相关。

核心结论

  • 肾移植受者骨骼异常在6个月后大多稳定或改善,但皮质骨进行性变薄持续存在。

研究设计与样本

  • 24个月前瞻性队列研究,纳入60例新发肾移植受者和361名健康对照,年龄20-60岁。

主要发现

  • 基线时肾移植受者的四肢骨骼肌质量指数、骨小梁和皮质骨容积骨密度、皮质厚度及髋部、股骨颈、超远端桡骨面积骨密度均低于对照(P ≤ 0.003)。
  • 移植后前6个月,四肢骨骼肌质量指数、脂肪质量指数和BMI增加(P < 0.001),而胫骨骨小梁容积骨密度和腰椎面积骨密度下降(P ≤ 0.005)。
  • 6个月后皮质骨容积骨密度增加(P < 0.001),与甲状旁腺激素水平下降相关(P = 0.004);6至24个月皮质厚度下降(P = 0.002),因骨内膜骨丢失。
  • 总髋和股骨颈面积骨密度6个月内稳定,之后至24个月改善(P ≤ 0.02);超远端桡骨面积骨密度在整个研究期间下降(P ≤ 0.003)。
  • 较高的BMI和四肢骨骼肌质量指数与髋部和脊柱面积骨密度及骨小梁容积骨密度增加相关(均P ≤ 0.02);糖皮质激素剂量与脊柱和髋部面积骨密度及皮质骨和骨小梁容积骨密度变化负相关(均P ≤ 0.02)。

临床怎么用

  • 肾移植后应关注糖皮质激素对骨骼的不利影响,并监测骨密度和骨结构变化。
  • 维持或增加肌肉质量和BMI可能有助于改善肾移植后负重骨骼的骨健康。

局限性

  • 结果不能推广至年龄较大的肾移植受者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Kidney transplant (KT) ameliorates the underlying abnormalities contributing to skeletal fragility in chronic kidney disease, but fracture rates increase after transplant. This study sought to assess the impact of changes in body composition and mineral metabolism on bone mineral density (BMD) and structure following kidney KT. STUDY DESIGN: 24-month prospective cohort study. SETTING & PARTICIPANTS: 60 incident KT recipients and 361 healthy controls aged 20-60 years. OUTCOMES: Tibia volumetric BMD (vBMD) and cortical dimensions measured using peripheral quantitative computed tomography and areal BMD (aBMD), appendicular lean mass index (ALMI), and fat mass index measured using dual-energy X-ray absorptiometry. ANALYTICAL APPROACH: Analytical Approach: Outcomes were converted to sex-specific z scores for age and compared with those in 361 controls. Quasi-least-squares regression models identified correlates of change. RESULTS: At baseline, ALMI, trabecular and cortical vBMD, cortical thickness, and total hip, femoral neck, and ultradistal radius aBMD were lower in KT recipients versus controls (P ≤ 0.003). During the first 6 months after KT, ALMI, fat mass index, and body mass index (BMI) increased (P < 0.001), whereas tibia trabecular vBMD and lumbar spine aBMD decreased (P ≤ 0.005). Cortical vBMD increased from 6 months onward (P < 0.001) in association with decreasing parathyroid hormone levels (P = 0.004). Cortical thickness decreased between 6 and 24 months (P = 0.002) because of a loss of endocortical bone. Total hip and femoral neck aBMD remained stable for 6 months, then improved through 24 months (P ≤ 0.02). Ultradistal radius aBMD decreased throughout the study (P ≤ 0.003). Higher BMI and ALMI were associated with gains in hip and spine aBMD and trabecular vBMD (all P ≤ 0.02). Corticosteroid dose was negatively associated with changes in spine and hip aBMD and cortical and trabecular vBMD (all P ≤ 0.02). Higher bone turnover marker levels and loss of cortical vBMD and thickness were associated with increases in serum calcium concentrations (P ≤ 0.03). LIMITATIONS: Not generalizable to older KT recipients. CONCLUSIONS: Skeletal deficits in KT recipients largely stabilize or improve beyond 6 months, with the exception of progressive cortical thinning. Strategies are needed to preserve cortical bone before and after KT. Gains in BMI and ALMI may improve bone health in the weight-bearing skeleton following KT. PLAIN-LANGUAGE SUMMARY: We enrolled 60 adults at the time of kidney transplant (KT) and compared measures of bone and muscle mass versus those in 361 healthy individuals. At the time of transplant, KT recipients had low muscle mass, low bone density, and thin bones compared with healthy individuals. After transplant, KT recipients rapidly gained muscle and fat. Despite the adverse effect of corticosteroid medications on bone, hip bone density improved significantly between 6 and 24 months. More muscle was associated with greater gains in hip and spine bone density over 2 years. In contrast, long bones got progressively thinner in association with biomarkers of bone breakdown. This study improves our understanding of the contributions of corticosteroids, muscle, and mineral metabolism on changes in bone density and thickness after KT, as well as the potential for recovery of bone density at selected skeletal sites.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Ziolkowski SL, Long J, Nickolas TL, et al. Corticosteroid, Parathyroid Hormone, and Body Composition Associations With Bone Density and Structure Following Kidney Transplantation. Am J Kidney Dis. 2025. PMID: 41205644. doi:10.1053/j.ajkd.2025.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。